Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.

Authors

Heinz-Josef Lenz

USC Norris Comprehensive Cancer Center, Los Angeles, CA

Heinz-Josef Lenz , Sara Lonardi , Vittorina Zagonel , Eric Van Cutsem , M. Luisa Limon , Mark Wong , Alain Hendlisz , Massimo Aglietta , Pilar Garcia-Alfonso , Bart Neyns , Fabio Gelsomino , Dana Backlund Cardin , Tomislav Dragovich , Usman Shah , Jing Yang , Jean-Marie Ledeine , Michael J. Overman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NTC02060188

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4040)

DOI

10.1200/JCO.2020.38.15_suppl.4040

Abstract #

4040

Poster Bd #

Abstract Disclosures

FEATURED

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.

Authors

Heinz-Josef Lenz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.

Poster

Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

Poster

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

Poster

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.